亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Preclinical Evaluation of [ 177 Lu]Lu-ART-101 for Radiopharmaceutical Therapy of Advanced Prostate Cancer

体内分布 LNCaP公司 内化 前列腺癌 毒性 医学 癌症研究 谷氨酸羧肽酶Ⅱ 体外 放射免疫疗法 前列腺 放射性核素治疗 体内 肿瘤科 内科学 药理学 癌症 治疗指标 剂量学 分布(数学) 药代动力学 化学 肿瘤细胞 细胞毒性 癌细胞 细胞 癌症治疗 化疗 核医学
作者
Malick Bio Idrissou,Carolina Aguiar Ferreira,Hansel Comas Rojas,Liudmila H. Lambert Lepesevich,Lauren E Wehner,Nathan Clemons,Yadira Medina-Guevara,Elizabeth Santos,Andres F. Mejia Montoya,Christopher Massey,Amanda Carston,John Munson,Anatoly N. Pinchuk,Gopal Iyer,Reinier Hernandez
出处
期刊:Journal of nuclear medicine [Society of Nuclear Medicine and Molecular Imaging]
卷期号:67 (5): 758-764
标识
DOI:10.2967/jnumed.125.271543
摘要

Radiopharmaceutical therapy with [177Lu]Lu-PSMA-617 has improved outcomes for patients with advanced prostate cancer (PCa), yet modest survival benefits underscore the need for more effective agents. Here, we describe the development of [177Lu]Lu-ART-101, a next-generation prostate-specific membrane antigen (PSMA)–targeting radioligand, and evaluate its biodistribution, dosimetry, therapeutic efficacy, and toxicity in advanced PSMA-expressing PCa models. Methods: Lipophilic ART-101 was synthesized and radiolabeled with 177Lu. [177Lu]Lu-ART-101 longitudinal biodistribution and dosimetry were assessed through SPECT/CT imaging in human PC3-PIP (PC3 cells engineered to overexpress PSMA) xenograft–bearing mice and compared with those of [177Lu]Lu-PSMA-617. The therapeutic efficacy of [177Lu]Lu-ART-101 was evaluated in the PC3-PIP and LNCaP xenograft–bearing mice, whereas toxicity was assessed in normal ICR mice. Results: [177Lu]Lu-ART-101 demonstrated patterns of cell binding and internalization similar to those of [177Lu]Lu-PSMA-617 in PC3-PIP cells. Internalization was effectively blocked by PSMA-617, indicating the PSMA-specific binding of [177Lu]Lu-ART-101. In vitro competition assays revealed potent nanomolar binding, with unlabeled ART-101 competitively displacing [177Lu]Lu-PSMA-617, with 0.4 ± 0.1 nM of inhibitory concentration of 50%, in PC3-PIP cells. In nude mice bearing PC3-PIP xenografts, [177Lu]Lu-ART-101 displayed higher tumor uptake (peak at 14.3 ± 1.5 %IA/g at 48 h after injection) and prolonged retention (8.1 ± 0.8 and 6.4 ± 1.0 %IA/g at 120 and 168 h, respectively) versus [177Lu]Lu-PSMA-617 (peak at 10.0 ± 2.0 %IA/g at 2 h) followed by a rapid decrease (2.2 ± 1.5 %IA/g at 120 h), leading to a 2-fold higher tumor absorbed dose with [177Lu]Lu-ART-101 (1.2 ± 0.1 vs. 0.6 ± 0.1). Notably, [177Lu]Lu-ART-101 showed a distinctive normal tissue distribution compared with [177Lu]Lu-PSMA-617, with longer blood circulation, negligible salivary gland uptake, and primarily hepatic rather than renal clearance. [177Lu]Lu-ART-101’s favorable tumor dosimetry translated to enhanced tumor control and prolonged survival in both the PC3-PIP and LNCaP xenograft models. Safety studies in ICR mice revealed mild transient cytopenia in animals receiving the highest tested injected activity (55.5 MBq), which resolved by day 28, without concomitant renal, hepatic, or histologic abnormalities, including those in the bone marrow and salivary glands. Conclusion: [177Lu]Lu-ART-101 demonstrates significant potential as a novel radiopharmaceutical for advanced PCa, with superior therapeutic efficacy and a favorable safety profile. These findings support our ongoing clinical translation effort in advanced PCa.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
194完成签到,获得积分10
4秒前
idiot17完成签到,获得积分10
7秒前
如花完成签到 ,获得积分10
8秒前
12秒前
顺利的山柳完成签到,获得积分10
15秒前
共享精神的应助被科研小白采纳,获得10
17秒前
卿亦佳人发布了新的文献求助30
18秒前
corleeang完成签到 ,获得积分10
20秒前
mangle完成签到,获得积分10
21秒前
小张完成签到 ,获得积分10
22秒前
idiot17关注了科研通微信公众号
24秒前
乐研客完成签到,获得积分10
25秒前
26秒前
情怀的应助被独特幻然采纳,获得10
27秒前
高高笙完成签到,获得积分10
28秒前
28秒前
30秒前
朴实寻双发布了新的文献求助10
32秒前
美满惜雪发布了新的文献求助10
36秒前
朴实寻双完成签到,获得积分10
41秒前
卿亦佳人发布了新的文献求助10
42秒前
叆叇完成签到,获得积分10
43秒前
肖坤完成签到,获得积分10
43秒前
47秒前
无语的小李完成签到,获得积分10
47秒前
科研小白发布了新的文献求助10
52秒前
科研小白完成签到,获得积分10
54秒前
丰富的雅绿完成签到,获得积分10
1分钟前
复杂的士萧完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
卉卉完成签到,获得积分10
1分钟前
林xq完成签到 ,获得积分10
1分钟前
愉快的泥猴桃完成签到 ,获得积分10
1分钟前
黄黄胖胖的龙完成签到,获得积分10
1分钟前
标致访旋完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184991
求助须知:如何正确求助?哪些是违规求助? 9573924
关于积分的说明 21833782
捐赠科研通 7782458
什么是DOI,文献DOI怎么找? 3434459
关于科研通互助平台的介绍 2558672
邀请新用户注册赠送积分活动 2481161